Skip to Content
Søg Menu
9.-13. september 2022

Vi var på ESMO 2022 I European Society for Medical Oncology

Seneste fra ESMO 2022

Endocrine Response for Routine Decision-making on Chemotherapy use in HR+/HER2-N0-1 Early Breast Cancer

  • / Nadia Harbeck

SABCS Kongresside

Her finder du abstracts, online artikler, MEDtalks med internationale og nationale key opinion leaders fra SABCS

Se mere

MCED blood test – a gamechanger for early cancer detection for cancer

/ Hæmatologi / BestPractice Nordic

Air pollution and lung cancer in never-smoking people 

/ Onkologi / BestPractice Nordic

Tumor-infiltrating lymphocytes improves PFS in metastatic melanoma

/ Onkologi / BestPractice Nordic

Combination of abemaciclib and trastuzumab +/- fulvestrant improved OS in women with HR+, HER2+ advanced breast cancer  

/ Onkologi / BestPractice Nordic

A major threat to human health

/ Onkologi / BestPractice Nordic

MEDtalks fra ESMO 2022

Current landscape in the immuno-oncology treatment of non-melanoma skin cancers

/ Onkologi / Paolo Antonio Ascierto

Sexual health in long-term breast cancer survivors

/ Onkologi / Solveig Katrine Smedsland

ICON trial update: Ipi+Nivo combination with chemotherapy does not improve survival

/ Onkologi / Jon Amund Kyte

The clinical value of circulating tumor DNA in bladder and renal cancer

/ Onkologi / Lars Dyrskjøt Andersen

Outstanding results of ovarian cancer treatment

/ Onkologi / Clare Scott
Se oversigt

Optimizing the front-line PARP-inhibitor treatment of ovarian cancer from a Nordic perspective

/ Onkologi / Kristina Lindemann

Efficacy of trastuzumab-deruxtecan therapy in HER2-positive breast cancer

/ Onkologi / Angelika Starzer

ESMO Highlights: Promising data for the frontline treatment of gynecologic cancer

/ Onkologi / Kristina Lindemann

ESMO Highlights: Increase awareness of supportive and palliative care for patients with cancer

/ Onkologi / Christina H. Ruhlmann

ESMO Highlights: Practical changes for treatment of lower gastrointestinal tumors

/ Onkologi / Marco Gerlinger

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

/ Onkologi / Siow Ming Lee

Klinik for senfølger efter kræft: 80% af de besøgende er kvinder

/ Almen praksis / Karin Brochsted Dieperink

COSMIC-313 – the first metastatic renal cell carcinoma (RCC) phase 3 trial with a doublet nivolumab plus ipilimumab

/ Onkologi / Toni K. Choueiri

Overraskende resultater ved aktiv brug af PRO under behandling af blærecancer

/ Onkologi / Gry Assam Taarnhøj

Two years of ADT reduce the risk of metastases in patients undergoing post-prostatectomy radiotherapy

/ Onkologi / Chris Parker

Tema: Lungecancer

The link between air pollution and NSCLC – in people who have never smoked

  • / Charles Swanton

Firstline nivolumab plus ipilimumab shows durable OS after 4 years in patients with pleural mesothelioma

/ Onkologi / Gerard Zalcman

Nye senfølgeklinikker efter kræftbehandling: Erfaringer og konklusioner direkte fra ESMO22

/ Onkologi / Karin Brochsted Dieperink

The MCED blood test – A possible new era of early cancer detection

/ Onkologi / Deborah Schrag

Cell therapy improves progression-free survival with 50% in advanced melanoma

/ Onkologi / John Haanen

PARP inhibitors are showing promising results in treating ovarian cancer 

/ Onkologi / BestPractice Nordic

Abstracts fra ESMO 2022

Doublet immune therapy for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy 

/ BestPractice Nordic
ESMO22Nyrecancer

ESMO 2022 –” Understanding the disease to provide better care for cancer patients”  

/ BestPractice Nordic
ESMO22

Faglig test – Pulmonalt planocellulært karcinom

Test din viden om pulmonalt planocellulært karcinom

Tag testen her

ESMO 2021

Maintenance olaparib rechallenge in patients with ovarian carcinoma benefit outcomes

/ Eric Pujade-Lauraine
ESMO21Gynækologisk cancer Play the Video
Silvia Stacchiotti

Global consensus: Management of epithelioid hemangioendothelioma

/ Silvia Stacchiotti
ESMO21Cancer Play the Video
Eric Pujade-Lauraine

PARP inhibitor olaparib shows significant improvement in PFS for patients with relapsed platinum-sensitive ovarian cancer

/ Eric Pujade-Lauraine
ESMO21Gynækologisk cancer Play the Video
Alan Celik

HER2-positiv brystcancer – fremtidige behandlingsmuligheder

/ Alan Celik
ESMO21Brystcancer Play the Video
Lene Bæksgaard Jensen

Opdatering på CheckMate 649-studiet

/ Lene Bæksgaard
ESMO21Kemoterapi Play the Video
Dana Chase

High-risk factors in patients with advanced ovarian cancer impact survival

/ Dana Chase
ESMO21Gynækologisk cancer Play the Video
Hent flere

Highlights fra ESMO 2021 (2:2)

/ Tine McCulloch / Weronika Szejniuk
ESMO21Lungecancer Play the Audio 13:00

ESMO 2021 – Highlights om lungecancer (1:2)

/ Tine McCulloch / Weronika Szejniuk
ESMO21Lungecancer Play the Audio 14:41

MEDtalks fra ESMO 2020

Højdosis strålebehandling ved småcellet lungekræft i begrænset stadium

/ Bjørn Henning Grønberg
LungecancerESMO20

ESMO20: Update om lungecancer

/ Bjørn Henning Grønberg
LungecancerESMO20 Play the Video

ESMO20: Improved OS rate for metastatic, PD-L1-positive lung cancer patients

/ Julie Brahmer
LungecancerESMO20 Play the Video

PIONeeR-studiet bringer os tættere på forståelsen af resistens mod PD-1/L1 inhibitorer

LungecancerESMO20

Lovende effekt på hjernemetastaser placerer osimertinib som adjuverende behandling af EGFR-positiv ikke-småcellet lungecancer

HjernemetastaserLungecancerESMO20

Lorlatinib har potentiale til at blive ny førstelinjebehandling til lokal fremskreden og metastatisk ALK positiv NSCLC

NSCLCLungecancerESMO20
Se mere fra ESMO
Back to top